Skip to main content

Table 1 Characteristics of study population in the derivation and validation cohorts

From: Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study

VariableDerivation (n = 200)Validation (n = 200)p
Age60 (49.5–69)67 (59–78)< 0.001
Male gender110 (55.0%)105 (52.5%)0.62
Race
 Caucasian110 (55.0%)106 (53%)< 0.001
 African American82 (41.0%)24 (12.0%)
 Asian4 (2.0%)50 (25.0%)
 Other4 (2.0%)20 (10.0%)
Diabetes mellitus59 (29.5%)57 (28.5%)0.83
Cirrhosis20 (10.0%)17 (8.5%)0.61
Immunocompromised95 (47.5%)27 (13.5%)< 0.001
Pneumonia78 (39.0%)104 (52.5%)0.007
APACHE II25 (19.5–32.5)25 (19–33)0.99
Septic shock at presentation77 (38.5%)98 (49.0%)0.034
Invasive ventilation at presentation82 (41.0%)82 (41.0%)1.0
ARDS57 (28.5%)50 (25.3%)0.47
30-day mortality82 (41.0%)54 (27.0%)0.003
sTNFR1 (pg/ml)8444 (4332–13,450)6366 (3232–11,024)0.004
IL8 (pg/ml)115.7 (51.2–325.6)54.7 (23.5–241.0)< 0.001
Ang2 (pg/ml)13,933 (8747–26,865)13,894 (7146–24,447)0.24
  1. Abbreviations: APACHE Acute Physiology, Age and Chronic Health Evaluation, ARDS acute respiratory distress syndrome, sTNFR1 soluble tumor necrosis factor receptor-1, IL interleukin, Ang2 angiopoietin-2